Compositions comprising probiotics for telomerase production

Abstract

A composition comprising a recombinant probiotic organism reengineered to constitutively express an enzyme involved in the maintenance of telomere length wherein the enzyme comprises a telomerase subunit, the genetic modification comprising an operon, a telomerase subunit, a telomerase subunit, a telomerase subunit, a telomerase subunit, a telomerase subunit, a telomerase subunit, a telomerase subunit, and a telomerase subunit. The operon comprises a promoter recognized by an RNA polymerase of the probiotic organism and a gene sequence encoding a telomerase, has a genetic modification that induces secretion of the telomerase into the host organism, and the genetic modification of the telomerase gene sequence enhances telomerase entry into cells of the host organism.

Description

Technical Field

[0001] The claimed implementation schemes generally relate to health supplements, and more specifically, to compositions comprising probiotics for enhancing telomerase production. Background Technology

[0002] Longevity and health maintenance have long been a focus of biomedical research, particularly in the context of cellular senescence and its impact on overall health. At the heart of the aging process is the gradual shortening of telomeres, the protective caps at the ends of chromosomes, which occurs with each cell division. Telomere length is a key factor in cellular senescence (the point at which cell division ceases). Therefore, maintaining or extending telomere length is of great significance for promoting health and potentially extending lifespan.

[0003] Historically, methods for regulating telomere length have primarily focused on direct genetic interventions, pharmaceuticals, and various lifestyle modifications, each with varying degrees of success and practicality. Telomerase has been identified as a key player in maintaining telomere length, capable of adding telomeric DNA to the ends of chromosomes to counteract the natural process of telomere loss. However, effective and safe methods to enhance human telomerase activity remain elusive.

[0004] Current strategies for maintaining telomere length face several challenges, including delivering therapeutic agents in a way that is both effective and safe, targeting therapies to appropriate cells, and achieving sustained telomerase activity without adverse effects. Furthermore, there is a need for easily accessible, non-invasive interventions that are compatible with daily life; many current approaches do not adequately address these issues.

[0005] Existing technologies have revealed attempts to directly manipulate telomerase activity through gene therapy and pharmacological agents; however, these methods are often accompanied by significant risks, such as an increased likelihood of cancer development, and practical limitations in delivery and specificity of action. Furthermore, the use of synthetic compounds or highly engineered biologics raises concerns about long-term safety and regulatory approval.

[0006] Therefore, there is a clear unmet need in the existing technology for innovative solutions that can safely and effectively modulate telomerase activity to address the fundamental challenge of telomere loss in cellular senescence. Summary of the Invention

[0007] This summary is provided to present, in a simplified form, excerpts of the disclosed concepts further described below, including the accompanying drawings. This summary is not intended to define key or essential features of the claimed subject matter. Nor is it intended to limit the scope of the claimed subject matter.

[0008] The disclosed embodiments relate to a composition comprising a recombinant probiotic organism engineered to constitutively express an enzyme involved in maintaining telomere length, wherein the enzyme comprises a telomerase subunit, the genetic modification comprising an operon containing a promoter recognized by the probiotic organism's RNA polymerase and a gene encoding telomerase, the bacteria comprising a genetic modification that induces telomerase secretion into a host organism, and the genetic modification of the telomerase gene sequence enhancing telomerase entry into the host organism's cells.

[0009] To achieve the foregoing and related objectives, the claimed subject matter may be embodied in the form illustrated in the accompanying drawings. However, it should be noted that the drawings are merely exemplary and that changes may be made to the specific structures illustrated and described in the drawings within the scope of the appended claims. The foregoing and other features and advantages of the claimed embodiments will become apparent from the following more specific description of preferred embodiments, as illustrated in the accompanying drawings. Attached Figure Description

[0010] The accompanying drawings, incorporated in and forming part of this specification, illustrate embodiments of the claimed subject matter and, together with the specification, serve to explain the principles of the disclosed embodiments. The embodiments illustrated herein are currently preferred; however, it should be understood that the claimed subject matter is not limited to the precise arrangements and means illustrated, wherein:

[0011] Figure 1 This is an illustration depicting a composition in powder form containing probiotics for enhancing telomerase production according to one embodiment;

[0012] Figure 2 This is an illustration depicting a capsule-shaped composition containing probiotics for enhancing telomerase production according to one embodiment;

[0013] Figure 3 This is an illustration depicting a capsule-shaped composition containing probiotics for enhancing telomerase production according to one embodiment;

[0014] Figure 4 The illustration depicts a composition comprising probiotics for enhancing telomerase production, according to one embodiment, in various ready-to-eat food forms. Detailed Implementation

[0015] The following detailed description refers to the accompanying drawings. Wherever possible, the same reference numerals are used in the drawings and the following description to refer to the same or similar elements. While the disclosed embodiments may be described, modifications, adjustments, and other practices are possible. For example, elements illustrated in the drawings may be replaced, added, or modified, and the methods described herein may be modified by replacing, reordering, or adding additional stages or components to the disclosed methods and apparatus. Therefore, the following detailed description of the invention does not limit the disclosed embodiments. Rather, the appropriate scope of the disclosed embodiments is defined by the appended claims.

[0016] The claimed implementation schemes described herein enhance the body's ability to combat aging. These schemes represent a significant advancement over existing technologies in the field of longevity and health maintenance, particularly in addressing the challenge of telomere loss, a key factor in cellular aging. Traditional methods for maintaining or extending telomere length primarily focus on direct genetic interventions, pharmaceuticals, and various lifestyle modifications. While these methods offer some benefits, they are limited by issues related to delivery, targeting, safety, and practicality. For example, gene therapy and pharmacological agents face obstacles due to their potential for carcinogenesis, difficulty in targeting specific cells, and the challenge of achieving sustained activity without adverse reactions. Furthermore, reliance on synthetic compounds or highly engineered biological agents raises concerns about long-term safety and regulatory approval.

[0017] The claimed implementation provides a novel solution by utilizing recombinant probiotic organisms engineered to constitutively express telomerase, the enzyme responsible for adding DNA sequences to the ends of chromosomes, thereby counteracting telomere shortening. Unlike previous methods, this approach offers a non-invasive, readily available, and potentially safer alternative for enhancing human telomerase activity. By incorporating genetic modifications into probiotic organisms already recognized for their health benefits, the claimed implementation addresses delivery and specificity issues by leveraging the natural mechanisms by which probiotics interact with and influence the host biological system. This ensures that the therapeutic telomerase is directly produced and secreted into the host organism, targeting cells more effectively and reducing the risk of adverse reactions associated with other delivery methods.

[0018] Furthermore, the use of probiotics circumvents restrictions associated with synthetic compounds and gene therapy, offering a solution that is more likely to be accepted by regulatory agencies and perceived as safe by the public. The formulation's multiple uses, including options for incorporation into food, beverages, or direct supplementation, address the practicality and accessibility issues of previous methods, making it easier for individuals to integrate the solution into their daily routines.

[0019] By employing a novel, probiotic-based strategy to address the fundamental challenge of telomere loss, the claimed implementation not only overcomes significant limitations of existing technologies but also opens new avenues for promoting health and longevity. The claimed implementation's method of enhancing telomerase activity in a safe, effective, and user-friendly manner represents a significant advance in the fields of biomedicine and longevity research.

[0020] Figure 1 This is an illustration depicting a composition 100 containing probiotics for enhancing telomerase production, in powder form, according to one embodiment. Figure 1 The composition is shown to be provided to a consumer in powder form 100 within a container 102, the container 102 having a removable top 104 for access to the interior. The powder can be ingested by mixing with a liquid such as water or milk, or it can be added to a solid food.

[0021] Figure 2 This is an illustration depicting a formulation in capsule form of a composition 100 containing probiotics for enhancing telomerase production according to one embodiment. Figure 2 The composition is shown to be available to a consumer in capsule form 200 within container 202, which has a removable top 204 for access to the interior of the container.

[0022] Figure 3 This is an illustration depicting a capsule-shaped composition 100 containing probiotics for enhancing telomerase production according to one embodiment. Figure 3 The image shows composition 100 provided in capsule 300, comprising a first portion 302 and a second portion 304, wherein composition 100 is present in powder form within the capsule. The design of capsule 300, including its composition, shell thickness, and any special coatings, can affect the release rate and absorption characteristics of composition 100. Some capsules are designed for immediate release, while others are formulated for sustained or delayed release to provide a more prolonged effect.

[0023] Figure 4 This is an illustration depicting a composition 100 containing probiotics for enhancing telomerase production, according to one embodiment, in various ready-to-eat food forms. Figure 4The composition 100 is shown to be available in various ready-to-eat food forms, wherein the composition 100 is present in, for example, sour cream 402, fermented pickles 404, apple cider vinegar 408, and yogurt 406. Other examples of ready-to-eat food forms include brine-cured olives, cheese, cottage cheese, cultured buttermilk, kefir, kimchi, kombucha, koumiss, kvass, miso, natto, sauerkraut, tempeh, viili yogurt, and water kefir.

[0024] The claimed composition 100 represents a breakthrough approach to promoting longevity and cellular health by maintaining telomere length. The claimed composition comprises genetically engineered probiotic organisms. These organisms are engineered to constitutively express telomerase, an enzyme that plays a crucial role in the elongation and maintenance of telomeres. Telomeres are protective caps at the ends of chromosomes, playing a key role in cellular senescence by protecting the chromosome ends from degeneration. With cell division, telomeres gradually shorten, leading to cellular senescence or loss of the ability to divide and grow. This is a natural process of aging and a key area of ​​interest for extending health and lifespan.

[0025] The genetically engineered probiotic organisms in the claimed composition are produced using recombinant DNA technology, which allows for the introduction of novel genetic material. The introduced genetic modifications include operons, a cluster of genes that operates under the control of a single promoter. A promoter is a DNA sequence recognized by the organism's RNA polymerase, initiating the transcription of the gene it controls—in this case, the gene encoding telomerase. This strategic modification ensures that the probiotics continuously produce telomerase. Furthermore, the bacteria are engineered to secrete telomerase, facilitating its delivery to the host organism and promoting telomere length maintenance from within. Note that the genetic modification of the telomerase gene sequence enhances telomerase entry into the host organism's cells.

[0026] RNA polymerase is a key enzyme found in all living organisms, playing a fundamental role in transcription, the first step in gene expression. During transcription, RNA polymerase reads the DNA template strand and synthesizes a complementary strand of RNA. Depending on the gene being transcribed, this RNA strand can be messenger RNA (mRNA), transfer RNA (tRNA), or ribosomal RNA (rRNA). Each type of RNA has a specific function in the cell: mRNA acts as a template for protein synthesis during translation, tRNA carries amino acids to ribosomes for protein assembly, and rRNA forms the core of the ribosome structure and catalyzes protein synthesis.

[0027] The claimed compositions specify organisms belonging to various genera, which are terms in biological taxonomy that indicate a rank grouping species exhibiting common characteristics together. The selected genera include *Bacillus*, *Bifidobacterium*, *Enterococcus*, *Escherichia*, and several other genera within the *Lactobacillus* group, each known for its health-promoting properties. The claimed compositions are further narrowed to specific species within these genera, such as *Bacillus subtilis* and *Bifidobacterium bifidum*, selected for their proven safety and efficacy as probiotics.

[0028] The probiotic organisms in the claimed composition belong to the genera selected from the following: Bacillus, Bifidobacterium, Enterococcus, Escherichia, Fructilactobacillus (formerly known as Lactobacillus), Lacticaseibacillus (formerly known as Lactobacillus), Lactiplantibacillus (formerly known as Lactobacillus), Lactobacillus, and Lentilactobacillus. The genera *Lactobacillus*, *Lactobacillus*, *Limosilactobacillus*, *Loigolactobacillus*, *Lactococcus*, *Leuconostoc*, *Pediococcus*, *Saccharomyces*, *Streptococcus*, *Weissella*, and *Yarrowia* are all related to the *Lactobacillus* genus.

[0029] The claimed compositions include probiotic organisms selected from the following species: Bacillus subtilis, Bacillus amyloliquefaciens, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Fructilactobacillus fructivorans (formerly known as Lactobacillus fructivorans), and Lactobacillus casei (formerly known as Lactobacillus casei). Lactobacillus casei, Lactobacillus paracasei (formerly known as Lactobacillus paracasei), Lactobacillus rhamnosus (formerly known as Lactobacillus rhamnosus), Lactobacillus pentosus (formerly known as Lactobacillus pentosus), Lactobacillus plantarum (formerly known as Lactobacillus plantarum), Lactobacillus acidophilus, Lactobacillus delbrueckii (formerly known as Lactobacillus delbrueckii), Lactobacillus hilgardii (formerly known as Lactobacillus hilgardii), Lactobacillus kefiri (formerly known as Lactobacillus kefiri), Lactobacillus brevis (formerly known as Lactobacillus brevis), and Lactobacillus fermentum. Lactobacillus fermentum (formerly known as Lactobacillus fermentatus), Lactobacillus reuteri (formerly known as Lactobacillus reuteri), and Lactobacillus coryniformis (Lactobacillus coryniformis).Formerly known as *Lactobacillus*, *Lactococcus lactis* (formerly *Lactobacillus xylose*), *Leuconostoc cremoris*, *Leuconostoc mesenteroides*, *Leuconostoc pseudomesenteroides*, *Pediococcus acidilactici*, *Pediococcus damnosus*, *Pediococcus pentosaceus*, *Saccharomyces boulardii*, *Streptococcus lactis*, *Streptococcus thermophilus*, *Weissella cibaria* (formerly *Lactobacillus coprophilus*), and *Yarrowia lipolytica*.

[0030] To enhance telomerase expression and function using the claimed composition, additional genetic modifications were introduced. These modifications included nucleic acid sequences encoding transcription factors that regulate telomerase gene expression, ensuring efficient and effective enzyme production within the probiotic strain.

[0031] Probiotic compositions can be formulated into pharmaceutical compositions, incorporating pharmaceutically acceptable carriers to ensure safety and efficacy. The formulation is designed for multiple routes of administration, including surface, oral, or rectal administration, providing flexibility to meet diverse therapeutic needs and preferences. Stabilizers are also included to enhance the viability of the probiotic organisms during storage and at the time of administration, ensuring that the live bacteria remain active and effective in delivering telomerase to the host. The composition may also contain subunits that further enhance enzyme expression, encapsulated (as powder) or formulated into cultured ferments in food or beverages (such as sour cream, fermented pickles, apple cider vinegar, and yogurt), providing convenience and easy integration into daily routines. Protein subunits are polypeptide chains or individual protein molecules that assemble or “co-assemble” with other proteins to form protein complexes.

[0032] For oral administration, a key issue is protecting probiotic organisms as they travel through the acidic gastric environment to the intestines, where they can effectively colonize and express telomerase. This is typically addressed by employing advanced encapsulation technologies, such as microencapsulation or using enteric coatings that dissolve only at the higher pH levels present in the intestines. Formulations can be supplemented with prebiotics to nourish and enhance the survival and activity of probiotics, thereby ensuring their maximum therapeutic potential.

[0033] In the case of topical application, formulation strategies focus on enabling probiotics and telomerase to penetrate the skin barrier. This typically involves the use of delivery systems, such as liposomes or hydrogels, which can facilitate absorption through the skin layers. Such formulations are designed not only to maintain the viability of probiotics on the skin surface but also to ensure the stability and bioactivity of secreted telomerase, potentially contributing to skin health and anti-aging efforts.

[0034] For rectal administration, compositions are typically prepared in forms that allow direct delivery of probiotics to the lower gastrointestinal tract, such as suppositories or enemas. These formulations are designed to release their contents at body temperature upon insertion, placing the probiotics near their target site. This route is particularly effective for achieving high local concentrations of probiotics and enhancing their colonization and therapeutic activity. In all these administration methods, formulations are carefully designed to include stabilizers, preservatives, and nutrients that support the viability and function of the probiotics. Buffers may also be incorporated to maintain the optimal pH for probiotic survival and activity.

[0035] Stabilizers used in the claimed compositions ensure that the biological components maintain their viability, activity, and structural integrity from the point of manufacture to application. Polyols and sugars, such as trehalose, sorbitol, and mannitol, act as osmotic protectants. They protect proteins and cell membranes from dehydration and prevent osmotic stress during freeze-drying and storage. Proteins, such as skim milk, gelatin, and soy protein, act as protectants for probiotic cells and enzymes, forming a protective barrier that mitigates damage during freeze-drying, drying, and rehydration. Glycerol is used as a cryoprotectant in liquid formulations, protecting cells and enzymes from freezing and thawing by minimizing ice crystal formation and stabilizing cell membranes. Microencapsulated materials, including polymers such as alginate, chitosan, and polylactic-co-glycolic acid (PLGA), provide a physical barrier around probiotic cells or enzymes. This barrier not only protects against environmental stresses, such as pH and enzyme degradation, but also enables controlled release at the target site. Antioxidants, such as ascorbic acid (vitamin C) and tocopherol (vitamin E), are added to the formulation to prevent oxidative damage to probiotic cells and enzymes, which can lead to degradation of cellular components and loss of activity. Buffers such as phosphate, citrate, or acetate buffers maintain an optimal pH range, which is crucial for the stability and activity of probiotics and enzymes, as extreme pH levels can denature proteins and disrupt cell membranes. Finally, lyophilization protectants, including lactose and sucrose, are used during the freeze-drying process. They protect the structure and function of probiotic cells and enzymes during freeze-drying and subsequent rehydration.

[0036] In methods that enhance telomerase expression through recombinant probiotic organisms, the subunit that enhances enzyme expression plays a crucial role. This component is a finely regulated genetic or molecular addition designed to increase the level of telomerase production in the host organism. Enhancing enzyme expression through this subunit involves genetic engineering strategies aimed at increasing telomerase activity, a key factor in extending telomere length and potentially improving cell lifespan. The concept involves incorporating specific promoter sequences into the DNA of probiotics. These sequences serve as key starting points for transcription, acting as docking sites for RNA polymerases and other transcription factors, thereby determining the rate at which genes are transcribed into messenger RNA (mRNA). Using a strongly constitutively active promoter can lead to a significant increase in telomerase expression levels, ensuring efficient transcription.

[0037] Besides promoters, enhancer sequences also play a crucial role. These DNA elements can be placed at varying distances from the genes they regulate, binding to specific proteins that interact with the transcription mechanism. This interaction amplifies the transcription rate of telomerase genes, thereby increasing enzyme production. Regulatory elements are also key, providing precision in how telomerase expression is controlled within the host. These sequences allow for the tuning of enzyme production based on environmental cues or specific internal conditions, ensuring that telomerase is produced in a timely and spatially relevant manner. Furthermore, codon optimization is a strategy of customizing gene sequences to conform to the codon usage preferences of the host organism, improving the efficiency of the translation process. This tuning ensures that messenger RNA is translated into telomerase more efficiently, increasing overall productivity.

[0038] Essentially, the claimed composition utilizes a symbiotic relationship between humans and probiotics to provide a novel, non-invasive solution to the challenge of telomere loss, a fundamental aspect of cellular aging. By providing a detailed explanation of the scientific principles and methods employed, this specification highlights the innovative approach of the invention to enhance health and longevity by maintaining telomere length.

[0039] Although the subject matter has been described in language specific to structural features and / or methodological actions, it should be understood that the subject matter defined in the appended claims is not necessarily limited to the specific features or actions described above. Rather, the specific features and actions described above are disclosed as exemplary forms for implementing the claims.

[0040] We demand protection:

Claims

1. A composition comprising a recombinant probiotic organism, said recombinant probiotic organism being recombinantly engineered to constitutively express an enzyme involved in maintaining telomere length, wherein: a) The enzyme contains a telomerase subunit; b) The genetic modification includes an operon containing a promoter recognized by the RNA polymerase of the probiotic organism and a gene sequence encoding telomerase; c) The bacteria contain genetic modifications that induce telomerase secretion into the host organism; and d) Genetic modification of the telomerase gene sequence enhances telomerase entry into the host organism's cells.

2. The composition of claim 1, wherein the genetic modification comprises one or more nucleic acid sequences encoding transcription factors that regulate the expression of the telomerase gene in the probiotic organism.

3. The composition according to claim 2, wherein the probiotic organism belongs to a genera selected from the following: Bacillus, Bifidobacterium, Enterococcus, Escherichia, Lactobacillus fruitophilus (formerly known as Lactobacillus), Lactobacillus casei (formerly known as Lactobacillus), Lactobacillus plantarum (formerly known as Lactobacillus), Lactobacillus, Lactobacillus spp. (formerly known as Lactobacillus), Lactobacillus spp. (formerly known as Lactobacillus), Lactobacillus spp. (formerly known as Lactobacillus), Lactobacillus mucilaginosus (formerly known as Lactobacillus), Lactococcus spp. (formerly known as Lactobacillus xylose), Leuconostoc, Pediococcus, Saccharomyces, Streptococcus, Weissella (formerly known as Lactobacillus), and Yersinia.

4. The composition according to claim 2, wherein the probiotic organism is selected from the following species: Bacillus subtilis, Bacillus amyloliquefaciens, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Lactobacillus fructose-eating lactobacillus (formerly known as Lactobacillus fructose-eating), Lactobacillus casei (formerly known as Lactobacillus casei), Lactobacillus paracasei (formerly known as Lactobacillus paracasei), Lactobacillus rhamnosus (formerly known as Lactobacillus rhamnosus), Lactobacillus pentosus (formerly known as Lactobacillus pentosus), Lactobacillus plantarum (formerly known as Lactobacillus plantarum), Lactobacillus acidophilus, Lactobacillus delbrueckii. (formerly known as Lactobacillus lactis), Lactobacillus hilgardii (formerly known as Lactobacillus hilgardii), Lactobacillus kefiriensis (formerly known as Lactobacillus kefiriensis), Lactobacillus brevis (formerly known as Lactobacillus brevis), Lactobacillus fermentum (formerly known as Lactobacillus fermentum), Lactobacillus reuteri (formerly known as Lactobacillus reuteri), Lactobacillus corynebacterium (formerly known as Lactobacillus corynebacterium), Lactococcus lactis (formerly known as Lactobacillus xylose), Leuconostoc faecium, Leuconostoc mesenteroides, Leuconostoc pseudomesenteroides, Pediococcus acidophilus, Pediococcus toxicans, Pediococcus pentosus, Saccharomyces boulardii, Streptococcus lactis, Streptococcus thermophilus, Weissella stolonifera (formerly known as Lactobacillus fecalis), and Yersinia lipolytica.

5. The composition of claim 4, wherein the probiotic organism is formulated in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

6. The composition according to claim 5, wherein the pharmaceutical composition is formulated for topical, oral, or rectal application.

7. The composition of claim 6, further comprising a stabilizer to enhance the viability of the probiotic organism during storage and when applied to the host organism.

8. The composition of claim 7, wherein the telomerase enzyme comprises a subunit that enhances enzyme expression.

9. The composition according to claim 8, wherein the pharmaceutical composition is encapsulated in capsule form.

10. The composition according to claim 9, wherein the pharmaceutical composition is formulated in a culture ferment of food or beverage.

11. A composition comprising a recombinant probiotic organism, said recombinant probiotic organism being recombinantly engineered to constitutively express an enzyme involved in maintaining telomere length, wherein: a) The enzyme contains a telomerase subunit; b) The genetic modification includes an operon containing a promoter recognized by the RNA polymerase of the probiotic organism and a gene sequence encoding telomerase; c) The bacteria contain genetic modifications that optimize the expression of the telomerase gene; and d) Genetic modification of the telomerase gene sequence enhances telomerase entry into the host organism's cells.

12. The composition of claim 11, wherein the genetic modification comprises one or more nucleic acid sequences encoding transcription factors that regulate the expression of the telomerase gene in the probiotic strain.

13. The composition according to claim 12, wherein the probiotic organism belongs to a genera selected from: Bacillus, Bifidobacterium, Enterococcus, Escherichia, Lactobacillus fruitophilus (formerly known as Lactobacillus), Lactobacillus casei (formerly known as Lactobacillus), Lactobacillus plantarum (formerly known as Lactobacillus), Lactobacillus, Lactobacillus spp. (formerly known as Lactobacillus), Lactobacillus spp. (formerly known as Lactobacillus), Lactobacillus spp. (formerly known as Lactobacillus), Lactobacillus mucilaginosus (formerly known as Lactobacillus), Lactococcus spp. (formerly known as Lactobacillus xylose), Leuconostoc, Pediococcus, Saccharomyces, Streptococcus, Weissella (formerly known as Lactobacillus), and Yersinia.

14. The composition according to claim 13, wherein the probiotic organism is selected from the following species: Bacillus subtilis, Bacillus amyloliquefaciens, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Lactobacillus fructose-eating fruit-eating bacteria (formerly known as Lactobacillus fructose-eating bacteria), Lactobacillus casei (formerly known as Lactobacillus casei), Lactobacillus paracasei (formerly known as Lactobacillus paracasei), Lactobacillus rhamnosus (formerly known as Lactobacillus rhamnosus), Lactobacillus pentosus (formerly known as Lactobacillus pentosus), Lactobacillus plantarum (formerly known as Lactobacillus plantarum), Lactobacillus acidophilus, Lactobacillus delbrueckii. Lactobacillus (formerly known as Lactobacillus acidophilus), Lactobacillus hilgardii (formerly known as Lactobacillus hilgardii), Lactobacillus kefiriensis (formerly known as Lactobacillus kefiriensis), Lactobacillus brevis (formerly known as Lactobacillus brevis), Lactobacillus fermentum (formerly known as Lactobacillus fermentum), Lactobacillus reuteri (formerly known as Lactobacillus reuteri), Lactobacillus corynebacterium (formerly known as Lactobacillus corynebacterium), Lactococcus lactis (formerly known as Lactobacillus xylose), Leuconostoc mesenteroides, Leuconostoc mesenteroides, Leuconostoc pseudomesenteroides, Pediococcus acidophilus, Pediococcus toxicans, Pediococcus pentosaceus, Saccharomyces boulardii, Streptococcus lactis, Streptococcus thermophilus, Weissella foetida (formerly known as Lactobacillus fecalis), and Yersinia lipolytica.

15. The composition of claim 14, wherein the probiotic organism is formulated in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

16. The composition of claim 15, wherein the pharmaceutical composition is formulated for topical, oral, or rectal application.

17. The composition of claim 16, further comprising a stabilizer to enhance the viability of the probiotic organism during storage and when applied to the host organism.

18. The composition of claim 17, wherein the telomerase enzyme comprises a subunit that enhances enzyme expression.

19. The composition of claim 18, wherein the pharmaceutical composition is encapsulated in capsule form.

20. The composition of claim 19, wherein the pharmaceutical composition is formulated in a culture ferment of a food or beverage.

Images